X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Yorvipath (palopegteriparatide) is a prodrug of parathyroid hormone (PTH 1-34), which is designed to provide parathyroid hormone levels within the normal physiological range. It is approved for the treatment of adults with chronic hypoparathyroidism.
Lead Product(s): Palopegteriparatide
Therapeutic Area: Endocrinology Product Name: Yorvipath
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
The newly formed Eyconis has exclusive rights to develop and commercialize TransCon RBZ (ranibizumab) ophthalmology products globally, which are used for the treatment of wet age-related macular degeneration (AMD).
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: TransCon RBZ
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Eyconis
Deal Size: $248.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 29, 2024
Details:
Vector will employ its sales and marketing expertise to distribute both Skytrofa (lonapegsomatropin-tcgd) and Yorvipath in the GCC countries for pediatric growth hormone deficiency in the case of Skytrofa, and adult hypoparathyroidism in the case of Yorvipath.
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Product Name: Skytrofa
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Vector Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 08, 2024
Details:
Specialised Therapeutics will commercialise Ascendis' weekly injectable paediatric human growth hormone treatment SKYTROFA (lonapegsomatropin), hypoparathyroidism treatment YORVIPATH (palopegteriparatide) and investigational achondroplasia therapy TransCon CNP (navepegritide).
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Product Name: Skytrofa
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Specialised Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 07, 2024
Details:
TransCon hGH (lonapegsomatropin) is a once-weekly growth hormone, is designed to deliver unmodified somatropin. which is being evaluated in phase 3 clinical trials for the treatment of growth hormone deficiency.
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Product Name: TransCon hGH
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
TransCon PTH (palopegteriparatide) is an investigational prodrug of parathyroid hormone (PTH [1-34]) which is under development for the treatment of adult patients with hypoparathyroidism as a once-daily hormone replacement therapy.
Lead Product(s): Palopegteriparatide
Therapeutic Area: Endocrinology Product Name: TransCon PTH
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Under the agreement, Teijin will receive exclusive license to further develop and commercialize TransCon hGH (lonapegsomatropin-tcgd), TransCon PTH, and TransCon CNP for endocrinology rare disease, in Japan.
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Product Name: TransCon hGH
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Teijin Pharma
Deal Size: $245.0 million Upfront Cash: $70.0 million
Deal Type: Licensing Agreement November 29, 2023
Details:
Yorvipath (palopegteriparatide) is an investigational prodrug of parathyroid hormone (PTH) in development as a once-daily hormone replacement therapy. It is designed to restore physiologic levels of PTH 24 hours a day.
Lead Product(s): Palopegteriparatide
Therapeutic Area: Endocrinology Product Name: Yorvipath
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
TransCo PTH (palopegteriparatide) is an investigational prodrug of parathyroid hormone (PTH) in development as a once-daily hormone replacement therapy. It is designed to restore physiologic levels of PTH 24 hours a day.
Lead Product(s): Palopegteriparatide
Therapeutic Area: Endocrinology Product Name: TransCon PTH
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
Skytrofa (lonapegsomatropin) is designed to deliver unmodified somatropin, which is used for treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient endogenous growth hormone secretion (growth hormone deficiency, or GHD).
Lead Product(s): Lonapegsomatropin-tcgd
Therapeutic Area: Endocrinology Product Name: Skytrofa
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
